AIDS and Behavior

, Volume 12, Issue 2, pp 284–293 | Cite as

Initiation, Adherence, and Retention in a Randomized Controlled Trial of Directly Administered Antiretroviral Therapy

  • Duncan Smith-Rohrberg Maru
  • R. Douglas Bruce
  • Mary Walton
  • Jo Anne Mezger
  • Sandra A. Springer
  • David Shield
  • Frederick L. Altice
Original Paper

Abstract

Directly administered antiretroviral therapy (DAART) can improve health outcomes among HIV-infected drug users. An understanding of the utilization of DAART—initiation, adherence, and retention—is critical to successful program design. Here, we use the Behavioral Model to assess the enabling, predisposing, and need factors impacting adherence in our randomized, controlled trial of DAART versus self-administered therapy (SAT) among 141 HIV-infected drug users. Of 88 participants randomized to DAART, 74 (84%) initiated treatment, and 51 (69%) of those who initiated were retained in the program throughout the entire six-month period. Mean adherence to directly observed visits was 73%, and the mean overall composite adherence score was 77%. These results were seen despite the finding that 75% of participants indicated that they would prefer to take their own medications. Major causes of DAART discontinuation included hospitalization, incarceration, and entry into drug-treatment programs. The presence of depression and the lack of willingness to travel greater than four blocks to receive DAART predicted time-to-discontinuation.

Keywords

HIV Acquired immunodeficiency syndrome Substance abuse Directly administered antiretroviral therapy Adherence Directly observed therapy 

Notes

Acknowledgments

The authors would like to acknowledge the National Institutes on Drug Abuse (R01 DA13805) for funding this study as well as providing career development awards for FLA (K24 DA 0170720), SAS (K23 DA 019381-02) and RDB (K23 DA 022143). DSR receives funding from the National Institutes of Health Medical Science Training Program (GM07205). The funding sources played no role in design of the study, data collection, analysis or interpretation of results or in the writing of the report. The authors would like to thank James Taylor, Rodolfo Lopez, Angel Ojeda and Natalie Laurenco for their contribution to the study implementation. Without their active participation and attention to detail, this study would not have been possible. We additionally would like to thank Paula Dellamura for administrative support. Most importantly, we would like to thank the participants in this study who dedicated time and energy to make this research possible.

References

  1. Altice, F. L., & Friedland, G. H. (1998). The era of adherence to HIV therapy. Annals of Internal Medicine, 129, 503–505.PubMedGoogle Scholar
  2. Altice, F. L., Mezger, J. A., Hodges, J., Bruce, R. D., Marinovich, A., Walton, M., Springer, S., & Friedland, G. H. (2004). Developing a directly administered antiretroviral therapy intervention for HIV infected drug users: implications for program replication. Clinical Infectious Diseases, 38, S376–S387.PubMedCrossRefGoogle Scholar
  3. Altice, F. L., Mostashari, F., & Friedland, G. H. (2001). Trust and the acceptance of and adherence to antiretroviral therapy. Journal of the Acquired Immune Deficiency Syndromes (1999), 28, 47–58.Google Scholar
  4. Altice, F. L., Smith-Rohrberg, D., Bruce, R. D., Springer, S. A., & Friedland, G. H. (2007). Superiority of directly administered antiretroviral therapy compared to self-administered therapy among HIV-infected drug users: A randomized, controlled trial. Clinical Infectious Diseases, 45, 770–778.PubMedCrossRefGoogle Scholar
  5. Altice, F. L., Springer, S., Buitrago, M., Hunt, D. P., & Friedland, G. H. (2003). Pilot study to enhance HIV care using needle exchange-based health services for out-of-treatment injecting drug users. Journal of Urban Health, 80, 416–427.PubMedGoogle Scholar
  6. Andersen, R. M. (1995). Revisiting the behavioral model and access to medical care: Does it matter? Journal of Health and Social Behavior, 36, 1–10.PubMedCrossRefGoogle Scholar
  7. Andersen, R., & Aday, L. A. (1978). Access to medical care in the U.S.: Realized and potential. Medical Care, 16, 533–546.PubMedCrossRefGoogle Scholar
  8. Arnsten, J. H., Breg, K. M., Cooperman, N. A., Vinnanueva, M., Li, X., & Parker, F. (2007). A 6-month randomized controlled trial of directly observed therapy delivered in methadone clinics. Paper presented at the proceedings of the 2nd NIMH/IAPAC international conference on HIV treatment adherence, Jersey City, NJ.Google Scholar
  9. Arnsten, J. H., Demas, P. A., Farzadegan, H., Grant, R. W., Gourevitch, M. N., Chang, C. J., et al. (2001). Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: Comparison of self-report and electronic monitoring. Clinical Infectious Diseases, 33(8), 1417–1423.PubMedCrossRefGoogle Scholar
  10. Arnsten, J. H., Demas, P. A., Grant, R. W., Gourevitch, M. N., Farzadegan, H., Howard, A. A., et al. (2002). Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. Journal of General Internal Medicine, 17, 377–381.PubMedGoogle Scholar
  11. Behforouz, H. L., Kalmus, A., Scherz, C. S., Kahn, J. S., Kadakia, M. B., & Farmer, P. E. (2004). Directly observed therapy for HIV antiretroviral therapy in an urban US setting. Journal of the Acquired Immune Deficiency Syndromes, 36, 642–645.CrossRefGoogle Scholar
  12. Carretero, M. D., Burgess, A. P., Soler, P., Soler, M., & Catalan, J. (1996). Reliability and validity of an HIV-specific health-related quality-of-life measure for use with injecting drug users. AIDS, 10, 1699–1705.PubMedGoogle Scholar
  13. Conway, B., Prasad, J., Reynolds, R., Farley, J., Jones, M., Jutha, S., et al. (2004). Directly observed therapy for the management of HIV-infected patients in a methadone program. Clinical Infectious Diseases, 38, S402–S408.PubMedCrossRefGoogle Scholar
  14. Dalessandro, M., Conti, C. M., Gambi, F., Falasca, K., Doyle, R., Conti, P., et al. (2007). Antidepressant therapy can improve adherence to antiretroviral regimens among HIV-infected and depressed patients. Journal of Clinical Psychopharmacology, 27, 58–61.PubMedCrossRefGoogle Scholar
  15. Garland, W. H., Wohl, A. R., Valencia, R., Witt, M. D., Squires, K., Kovacs, A., et al. (2007). The acceptability of a directly-administered antiretroviral therapy (DAART) intervention among patients in public HIV clinics in Los Angeles, California. AIDS Care, 19, 159–167.PubMedCrossRefGoogle Scholar
  16. Gelberg, L., Andersen, R. M., & Leake, B. D. (2000). The behavioral model for vulnerable populations: Application to medical care use and outcomes for homeless people. Health Services Research, 34, 1273–1302.PubMedGoogle Scholar
  17. Greenberg, B., Berkman, A., Thomas, R., Hoos, D., Finkelstein, R., Astemborski, J., et al. (1999). Evaluating supervised HAART in late-stage HIV among drug users: A preliminary report. Journal of Urban Health, 76, 468–480.PubMedCrossRefGoogle Scholar
  18. Kozal, M. J., Amico, K. R., Chiarella, J., Cornman, D., Fisher, W., Fisher, J., et al. (2005). HIV drug resistance and HIV transmission risk behaviors among active injection drug users. Journal of Acquired Immune Deficiency Syndromes, 40(1), 106–109.PubMedCrossRefGoogle Scholar
  19. Lima, V. D., Geller, J., Bangsberg, D. R., Patterson, T. L., Daniel, M., Kerr, T., et al. (2007). The effect of adherence on the association between depressive symptoms and mortality among HIV-infected individuals first initiating HAART. AIDS, 21(9), 1175–1183.PubMedCrossRefGoogle Scholar
  20. Liu, H., Golin, C. E., Miller, L. G., Hays, R. D., Beck, C. K., Sanandaji, S., et al. (2001). A comparison study of multiple measures of adherence to HIV protease inhibitors. Annals of Internal Medicine, 134, 968–977.PubMedGoogle Scholar
  21. Liu, H., Miller, L. G., Hays, R. D., Golin, C. E., Wu, T., Wenger, N. S., et al. (2006). Repeated measures longitudinal analyses of HIV virologic response as a function of percent adherence, dose timing, genotypic sensitivity, and other factors. Journal of Acquired Immune Deficiency Syndromes, 41, 315–322.PubMedCrossRefGoogle Scholar
  22. Lucas, G. M., Cheever, L. W., Chaisson, R. E., & Moore, R. D. (2001). Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. Journal of Acquired Immune Deficiency Syndromes, 27, 251–259.PubMedGoogle Scholar
  23. Lucas, G. M., Gebo, K. A., Chaisson, R. E., & Moore, R. D. (2002). Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic. AIDS, 16(5), 767–774.PubMedCrossRefGoogle Scholar
  24. Lucas, G. M., Griswold, M., Gebo, K. A., Keruly, J., Chaisson, R. E., & Moore, R. D. (2006a). Illicit drug use and HIV-1 disease progression: A longitudinal study in the era of highly active antiretroviral therapy. American Journal of Epidemiology, 163(5), 412–420.PubMedCrossRefGoogle Scholar
  25. Lucas, G. M., Mullen, B. A., McCaul, M. E., Weidle, P. J., Hader, S., & Moore, R. D. (2007). Adherence, drug use, and treatment failure in a methadone-clinic-based program of directly administered antiretroviral therapy. AIDS Patient Care and STDs, 21(8), 564–574.PubMedCrossRefGoogle Scholar
  26. Lucas, G. M., Mullen, B. A., Weidle, P. J., Hader, S., McCaul, M. E., & Moore, R. D. (2006b). Directly administered antiretroviral therapy in methadone clinics is associated with improved HIV treatment outcomes, compared with outcomes among concurrent comparison groups. Clinical Infectious Diseases, 42(11), 1628–1635.PubMedCrossRefGoogle Scholar
  27. Lucas, G. M., Weidle, P. J., Hader, S., & Moore, R. D. (2004). Directly administered antiretroviral therapy in an urban methadone maintenance clinic: A nonrandomized comparative study. Clinical Infectious Diseases, 38, S409–S413.PubMedCrossRefGoogle Scholar
  28. Macalino, G. E., Hogan, J. W., Mitty, J. A., Bazerman, L. B., Delong, A. K., Loewenthal, H., et al. (2007). A randomized clinical trial of community-based directly observed therapy as an adherence intervention for HAART among substance users. AIDS, 21, 1473–1477.PubMedCrossRefGoogle Scholar
  29. Macalino, G. E., Mitty, J. A., Bazerman, L. B., Singh, K., McKenzie, M., & Flanigan, T. (2004). Modified directly observed therapy for the treatment of HIV-seropositive substance users: lessons learned from a pilot study. Clinical Infectious Diseases, 38, S393–S397.PubMedCrossRefGoogle Scholar
  30. Maru, D. S. R., Kozal, M. J., Bruce, R. D., Springer, S. A., & Altice, F. L. (2007). Directly administered antiretroviral therapy for HIV-infected drug users does not impact antiretroviral resistance: results from a randomized, controlled trial. Journal of the Acquired Immune Deficiency Syndromes, 46(5), 555–563.CrossRefGoogle Scholar
  31. Mitchell, C. G., Freels, S., Creticos, C. M., Oltean, A., & Douglas, R. (2007). Preliminary findings of an intervention integrating modified directly observed therapy and risk reduction counseling. AIDS Care, 19(4), 561–564.Google Scholar
  32. Mitty, J. A., Macalino, G. E., Bazerman, L. B., Loewenthal, H. G., Hogan, J. W., MacLeod, C. J., et al. (2005). The use of community-based modified directly observed therapy for the treatment of HIV-infected persons. Journal of Acquired Immune Deficiency Syndromes, 39, 545–550.PubMedGoogle Scholar
  33. Murri, R., Fantoni, M., Del Borgo, C., Izzi, I., Visona, R., Suter, F., et al. (1999). Intravenous drug use, relationship with providers, and stage of HIV disease influence the prescription rates of protease inhibitors. Journal of Acquired Immune Deficiency Syndromes, 22, 461–466.PubMedGoogle Scholar
  34. Paterson, D. L., Potoski, B., & Capitano, B. (2002). Measurement of adherence to antiretroviral medications. Journal of Acquired Immune Deficiency Syndromes, 31, S103–S106.PubMedGoogle Scholar
  35. Rockwell, R., Des Jarlais, D. C., Friedman, S. R., Perlis, T. E., & Paone, D. (1999). Geographic proximity, policy and utilization of syringe exchange programmes. AIDS Care, 11, 437–442.PubMedCrossRefGoogle Scholar
  36. Santos, C. Q., Adeyemi, O., & Tenorio, A. R. (2006). Attitudes toward directly administered antiretroviral therapy (DAART) among HIV-positive inpatients in an inner city public hospital. AIDS Care, 18, 808–811.PubMedCrossRefGoogle Scholar
  37. Smith-Rohrberg, D., & Altice, F. L. (2006). Randomized, controlled trials of directly administered antiretroviral therapy for HIV-infected patients: Questions about study population and analytical approach. Clinical Infectious Diseases, 43, 1221–1222.PubMedCrossRefGoogle Scholar
  38. Smith-Rohrberg, D., Mezger, J., Walton, M., Bruce, R. D., & Altice, F. L. (2006). Impact of enhanced services on virologic outcomes in a directly administered antiretroviral therapy trial for HIV-infected drug users. Journal of Acquired Immune Deficiency Syndromes, 43, S48–S53.PubMedCrossRefGoogle Scholar
  39. Tinoco, I., Giron-Gonzalez, J. A., Gonzalez-Gonzalez, M. T., Vergara de Campos, A., Rodriguez-Felix, L., Serrano, A., et al. (2004). Efficacy of directly observed treatment of HIV infection: Experience in AIDS welfare homes. European Journal of Clinical Microbiology and Infectious Diseases, 23, 331–335.CrossRefGoogle Scholar
  40. Tyndall, M., McNally, M., Lai, C., Zhang, R., Wood, E., Kerr, T., et al. (2007). Directly observed therapy programs for antiretroviral treatment among injection drug users in Vancouver: Access, adherence and outcomes. International Journal of Drug Policy, 18(4), 281–287.Google Scholar
  41. Visnegarwala, F., Rodriguez-Barradass, M. C., Graviss, E. A., Caprio, M., Nykyforchyn, M., & Laufman, L. (2006). Community outreach with weekly delivery of anti-retroviral drugs compared to cognitive-behavioural health care team-based approach to improve adherence among indigent women newly starting HAART. AIDS Care, 18, 332–338.PubMedCrossRefGoogle Scholar
  42. Wohl, A. R., Garland, W. H., Valencia, R., Squires, K., Witt, M. D., Kovacs, A., et al. (2006). A randomized trial of directly administered antiretroviral therapy and adherence case management intervention. Clinical Infectious Diseases, 42, 1619–1627.PubMedCrossRefGoogle Scholar
  43. Wu, A. W. (1999). MOS-HIV health survey: Users manual. John Hopkins University.Google Scholar
  44. Wu, A. W., Revicki, D. A., Jacobson, D., & Malitz, F. E. (1997). Evidence for reliability, validity and usefulness of the medical outcomes study HIV health survey (MOS-HIV). Quality of Life Research, 6, 481–493.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Duncan Smith-Rohrberg Maru
    • 1
  • R. Douglas Bruce
    • 1
  • Mary Walton
    • 1
  • Jo Anne Mezger
    • 1
  • Sandra A. Springer
    • 1
  • David Shield
    • 1
  • Frederick L. Altice
    • 1
  1. 1.Yale University AIDS ProgramNew HavenUSA

Personalised recommendations